MONTVALE, N.J., March 5 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its wholly-owned subsidiary, Duramed Pharmaceuticals, Inc., has filed suit against Watson Pharmaceuticals (NYSE: WPI) and its subsidiary, Watson Laboratories, Inc., for infringement of the patent protecting Duramed's SEASONIQUE(R) extended-cycle oral contraceptive product. The Company's SEASONIQUE Patent No. 7,320,969 is due to expire on January 30, 2024. In addition to the patent, the Company also has 3-year New Product Exclusivity for its SEASONIQUE product until May 25, 2009.
"We remain committed to enforcing our patent on our SEASONIQUE extended-cycle oral contraceptive product and will pursue all legal means necessary to prevent Watson from launching a generic product prior to patent expiry in 2024," said Bruce L. Downey, Barr's Chairman and CEO.
On January 22, 2008, the U.S. Patent and Trademark Office issued the
patent for the Company's SEASONIQUE extended-cycle oral contraceptive. The
Company immediately submitted the patent to the U.S. Food and Drug
Administration (FDA) for listing in the Orange Book. On January 22, 2008,
Watson notified the Company pursuant to the Hatch-Waxman Act that Watson
had filed an Abbreviated New Drug Application (ANDA) with the FDA for
SEASONIQUE and that Watson had amended its application to include a
paragraph IV certification asserting that the SEASONIQUE patent is invalid,
unenforceable or not infringed by Watson's ANDA product. Barr has filed to
enforce the patent and prevent Watson from marketing a competing product
prior to patent expiry in 2024. If Barr is unsuccessful in this litigation,
the Company may face generic competition for SEASONIQUE as early as May 25,
2009, the d
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved